* Grant funds single-dose H5N1 vaccine development
* Clinical trial to combine adjuvants and Medicago vaccine
TORONTO, Jan 11 (Reuters) - Medicago Inc MDG.TO will participate in an early-stage clinical trial of a vaccine designed for use in the event of an avian pandemic flu outbreak, the Canadian biotechnology company said on Tuesday.
The Quebec City-based biotech is developing a single-dose H5N1 influenza vaccine. It will take part in the trial with the Infectious Disease Research Institute, which was awarded a multi-million dollar grant from the U.S. Defense Department.
Medicago produces pandemic and seasonal flu vaccines from plants such as tobacco leaves. It uses proprietary technology to produce particles that resemble a virus, but are non-infectious and cannot replicate.
The trial will combine Medicago’s plant-made H5 virus-like particle vaccine with the institute’s vaccine adjuvant technology. Adjuvants are substances that improve an antigen’s ability to create an immune response in the body.
Last week, Medicago said a peer-reviewed journal published a report on its clinical trial for plant-based H5N1 vaccines. [ID:nN05272383] (Reporting by S. John Tilak) (firstname.lastname@example.org; +1 416 941 8067)
Our Standards: The Thomson Reuters Trust Principles.